Btk Inhibitor

Btk Inhibitors (199):

Art. -Nr.	Produktname	Wirkung	Reinheit

HY-110013

Terreic acid	Inhibitor
Terreic acid, a quinone epoxide antibiotic, acts as an effective Btk inhibitor. Terreic acid blocks the interaction between PKC and the pleckstrin homology domain of Btk. Terreic acid inhibits the binding of GST-BtkPH to PKC in lysates of HMC-1 human mast cells with an IC₅₀ of approximately 100 μM.

HY-160246

QL47B	Inhibitor
QL47B, a biotinylated analogue of QL47 (HY-80003), is a potent inhibitor of BTK, with an IC₅₀ value of 1.3 μM. QL47B has anti-tumor activity.

HY-133137A

SJF620 hydrochloride	Inhibitor	99.28%
SJF620 hydrochloride is a PROTAC connected by ligands for Cereblon and Btk with a DC₅₀ of 7.9 nM. SJF620 contains a Lenalidomide analog for recruiting CRBN.

HY-100659S

Dihydrodiol-Ibrutinib-d₅	Inhibitor	99.19%
Dihydrodiol-Ibrutinib-d5 is the deuterium labeled Dihydrodiol-Ibrutinib (HY-100659). Dihydrodiol-Ibrutinib is a dihydrodiol active metabolite of Ibrutinib (HY-10997), has inhibitory activity towards BTK approximately 15 times lower than that of ibrutinib.

HY-109143B

(R)-Elsubrutinib	Inhibitor	98.0%
(R)-Elsubrutinib ((R)-ABBV-105) is a Btk inhibitor. (R)-Elsubrutinib can be used in studies of immune diseases (such as rheumatoid arthritis, psoriasis, ankylosing spondylitis, asthma, systemic lupus erythematosus) and cancer.

HY-136113

Ibrutinib dimer	Inhibitor	98.27%
Ibrutinib dimer is a Dimer of Ibrutinib. Ibrutinib dimer is an impurity of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with an IC₅₀ of 0.5 nM.

HY-13036

(Rac)-IBT6A	Inhibitor	98.18%
(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC₅₀ of 0.5 nM.

HY-160246A

QL47B TFA	Inhibitor
QL47B TFA, a biotinylated analogue of QL47 (HY-80003), is a potent inhibitor of BTK, with an IC₅₀ value of 1.3 μM. QL47B TFA has anti-tumor activity.

HY-17600R

Acalabrutinib (Standard)	Inhibitor
Acalabrutinib (Standard) is the analytical standard of Acalabrutinib. This product is intended for research and analytical applications. Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL). Acalabrutinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13036B

IBT6A hydrochloride	Inhibitor	99.35%
IBT6A hydrochloride is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC₅₀ of 0.5 nM.

HY-151808

JS25	Inhibitor	98.37%
JS25 is a selective and covalent inhibitor of BTK that inactivates BTK with an IC₅₀ value of 5.8 nM by chelating Tyr551. JS25 inhibits cancer cells proliferation, pronounces cell death, and promotes murine xenograft model of Burkitt’s lymphoma. JS25 effectively crosses the blood-brain barrier.

HY-132196

BTK inhibitor 18	Inhibitor
BTK inhibitor 18 is a potent, selective,orally active and covalent Btk inhibitor with a IC₅₀ of 142 nM. BTK inhibitor 18 has anti-inflammatory activities.

HY-130255

BTK inhibitor 13	Inhibitor
BTK inhibitor 13 (compound 8) is a potent and selective Bruton's tyrosine kinase (BTK) inhibitor with an IC₅₀ of 1.2 nM.

HY-111781

Civorebrutinib	Inhibitor
Civorebrutinib (WS-413) is a selective, orally active BTK and TEC inhibitor with an IC₅₀ of <100 nM for both targets. Civorebrutinib inhibits B cell activation. Civorebrutinib significantly suppresses the in vivo growth of diffuse large B-cell lymphoma cells. Civorebrutinib can be used for the research of diffuse large B-cell lymphoma.

HY-115876

BTK-IN-5	Inhibitor
BTK-IN-5 is a covalent BTK inhibitor for researching medical conditions such as cardiovascular diseases, respiratory diseases, inflammation, and diabetes.

HY-174850

CFON-026	Inhibitor
CFON-026 is a selective, orally active and non-covalent BTK inhibitor with an IC₅₀ of 0.27  nM. CFON-026 has significant antitumor activity against wild-type BTK (TMD8 and REC-1) and all clinically relevant BTK resistance mutations (BTK C481S, T474I, L528W and V416L). CFON-026 induces complete tumor regression in TMD8 xenograft mice model. CFON-026 can be used for research of hematological cancers like chronic lymphocytic leukemia and waldenström macroglobulinemia.

HY-174129

TM471-1	Inhibitor
TM471-1 is an orally active and covalent Bruton's tyrosine kinase (BTK) inhibitor with IC₅₀ values of 1.3 nM (BTK^WT), >40,000 nM (BTK^C481S), 7.9 nM (TEC) and 12.4 nM (TXK). TM471-1 inhibits cell growth in vivo and in vitro, arrests cell cycle at G0/G1 phase and induces cell apoptosis.

HY-145373

BMS-986143	Inhibitor
BMS-986143 is an orally active, reversible BTK inhibitor with an IC₅₀ of 0.26 nM. BMS-986143 also inhibits TEC, BLK, BMX, TXK FGR, YES1, ITK with IC₅₀s of 3 nM, 5 nM, 7 nM, 10 nM, 15 nM,19 nM, 21 nM, respectively. BMS-986143 can be used for the research of autoimmune diseases.

HY-102036

G-744	Inhibitor
G-744 is a highly potent, selective and orally active Btk inhibitor with an IC₅₀ of 2 nM. G-744 is metabolically stable, well tolerated and efficacious to treat arthritis.

HY-156604

Cinsebrutinib	Inhibitor
Cinsebrutinib is a Bruton's tyrosine kinase inhibitor, extracted from patent WO2021207549 (compound 5-6). Cinsebrutinib has the potential for cancer study.

Name
Email *

	Sorry, but the email address you supplied was invalid.